Gurana continues to operate in a pandemic.
The end of January 2020 was a difficult period for many drug manufacturers in the world due to the rapid spread of the new coronavirus in China, which affected most Chinese API manufacturers, their activities were frozen or at least seriously slowed down.
Together with our manufacturers, we are constantly looking for solutions to improve this situation. We do our best to ensure stable supplies and provide our Russian partners with comprehensive and reliable information on the state of manufacturers in China so that they can best implement their production plans.
We guarantee our continued support and, through efficient service, ensure the supply of high-quality products.